VolitionRx slashes debt by $5 million and secures a conversion rights pause until 2027, effectively lowering the company's outstanding principal and stabilizing its capital structure.
VolitionRx has significantly strengthened its balance sheet by prepaying a portion of its convertible note, reducing the outstanding principal to $0.7 million. By securing a moratorium on conversion rights until January 2027, the company has effectively mitigated near-term equity dilution risks, providing a more stable capital structure for its ongoing operations.
The outstanding principal has been reduced to $0.7 million, with conversion rights paused until January 2027.
The conversion rights pause remains in effect unless the company's closing share price equals or exceeds $0.275.
VolitionRx Limited has successfully reduced its outstanding debt by over $5 million since June 30, 2026, following a partial prepayment of its convertible notes. The company also secured a strategic agreement to pause conversion rights until January 2027, significantly mitigating near-term dilution risks for shareholders.
The agreement reduces the company's debt burden and prevents immediate equity dilution by pausing conversion rights on its notes until 2027.